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Eph receptor tyrosine kinases (RTKs) and their membrane-bound ligands, the ephrins, are essential for embryonic vascular
development. Recently, it has been demonstrated that overexpression of specific Ephs and ephrins is associated with a poor
prognosis in human tumours. Our group has shown that EphB and the ephrin-B subfamilies are coexpressed in human colorectal
cancer, and ephrin-B2 is expressed at higher levels in human colorectal cancer than in adjacent normal mucosa. As the Eph/ephrin
system is involved in embryologic vasculogenesis and ephrin-B2 is expressed ubiquitously in all colon cancers studied in our
laboratory, we hypothesised that overexpression of ephrin-B2 in colon cancer cells may induce tumour angiogenesis and increase
tumour growth. To investigate this hypothesis, we stably transfected KM12L4 human colon cancer cells with ephrin-B2 to study its
effect on tumour growth in vivo. We found that overexpression of ephrin-B2 markedly decreased tumour growth in a mouse
xenograft model. Immunohistochemical staining showed that ephrin-B2 transfectants produced higher tumour microvessel density
and lower tumour cell proliferation than did parental or vector-transfected control cells. Using
51Cr-labelled red blood cells (RBCs) to
determine the functional blood volume in tumours, we demonstrated that tumours from ephrin-B2-transfected cells had significantly
decreased blood volume compared with tumours from parental or vector-transfected control cells. Evaluation of in vitro parameters
of cell cycle mediators demonstrated no alteration in the cell cycle. Although ephrin-B2 transfection increased tumour vessel density,
the decrease in blood perfusion suggests that these vessels may be ‘dysfunctional’. We conclude that overexpression of ephrin-B2
suppresses tumour cell growth and vascular function in this in vivo colon cancer model.
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The largest subfamily of receptor tyrosine kinases (RTKs), the Eph
family, and their ligands (ephrins), play important roles in
physiologic and pathologic vascular processes. Both the Ephs
(receptors) and ephrins (ligands) are divided into two groups, A
and B subfamilies (Eph Nomenclature Committee, 1997). The
binding of ephrin ligands to Eph receptors is dependent on cell–
cell interactions. The interactions of ephrins and Ephs have
recently been shown to function via bi-directional signalling. The
ephrins binding to Eph receptors initiate phosphorylation at
specific tyrosine residues in the cytoplasmic domain of the Eph
receptors. In response to Eph receptor binding, the ephrin ligand
also undergoes tyrosine phosphorylation, so-called ‘reverse’
signalling (Holland et al, 1996; Bruckner et al, 1997).
Eph RTKs and their ephrin ligands play important roles in
embryonic vascular development. Disruption of specific Eph
receptors and ligands (including ephrin-B2) leads to defective
vessel remodelling, organisation, and sprouting resulting in
embryonic death (Wang et al, 1998; Adams et al, 1999; Gale and
Yancopoulos, 1999; Helbling et al, 2000). Coordinated expression
of the Eph/ephrin system determines the phenotype of embryonic
vascular structures: ephrin-B2 is present on arterial endothelial
cells (ECs), whereas EphB4 is present on venous ECs (Gale and
Yancopoulos, 1999; Shin et al, 2001). Recently, specific Ephs and
ephrins have been implicated in tumour growth and angiogenesis.
The Ephs and ephrins have been found to be overexpressed in
many human tumours (Kiyokawa et al, 1994; Vogt et al, 1998;
Bruce et al, 1999; Tang et al, 1999a,b; Walker-Daniels et al, 1999;
Ogawa et al, 2000; Varelias et al, 2002), and higher expression
levels of Ephs and ephrins have been found to correlate with more
aggressive and metastatic tumours (Vogt et al, 1998; Nakamoto
and Bergemann, 2002).
Our group has shown that EphB and the ephrin-B subfamilies
are co-expressed in human colorectal cancer, and ephrin-B2
is expressed at higher levels in human colorectal cancer than
in adjacent normal mucosa (Liu et al, 2002). As the Eph/ephrin
system is involved in embryologic vasculogenesis and ephrin-B2
is expressed ubiquitously in all colon cancers studied in our
laboratory, we hypothesised that overexpression of ephrin-B2 in
colon cancer cells may induce tumour angiogenesis and increase
tumour growth. We found that overexpression of ephrin-B2 in
colon cancer cells did lead to an increase in tumour angiogenesis,
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sbut that these vessels were not functional. Paradoxically, over-
expression of ephrin-B2 was associated with a marked decrease in
tumour growth that was likely secondary to the development of an
inefficient vascular network.
MATERIALS AND METHODS
Cells and cell cultures
The KM12L4, KM20, KM23, KM12C, and KM12SM human colon
cancer cell lines were provided by Dr IJ Fidler (The University of
Texas M.D. Anderson Cancer Center, Houston, TX, USA)
(Morikawa et al, 1988). HT-29 (human colorectal cancer cells),
MRC-5 (human lung fibroblasts), 10T1/2 (murine fibroblasts),
CCD-33Co and CCD-112Co (human colorectal fibroblasts), and
human umbilical vein endothelial cells (HUVECs) were purchased
from the American Type Culture Collection (ATCC, Manassas, VA,
USA). MRC-5, CCD-33Co, CCD-112Co, and all colon cancer cell
lines were cultured in minimal essential medium (MEM)
supplemented with 10% foetal bovine serum (FBS), penicillin–
streptomycin, vitamins, sodium pyruvate, L-glutamine, and non-
essential amino acids (Life Technologies, Inc., Grand Island, NY,
USA). Murine 10T1/2 cells were grown in basal Eagle’s medium
supplemented with 10% FBS, and 2Uml
 1 penicillin–streptomy-
cin. HUVECs were cultured on 0.5% gelatin (Sigma Chemical Co.
St Louis, MO, USA) in modified MEM supplemented with 15%
FBS, 10ngml
 1 recombinant human basic fibroblast growth
factor, penicillin–streptomycin, vitamins, sodium pyruvate, L-
glutamine, and nonessential amino acids. All cells were grown at
371Ci n5 %C O 2 and 95% air.
Antibodies for immunohistochemistry
Antibodies for immunohistochemical analysis were obtained as
follows: rabbit anti-human ephrin-B2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rat anti-mouse CD31/
PECAM-1 antibody and peroxidase-conjugated rat anti-mouse
immunoglobulin G1 (IgG1) from Pharmingen (San Diego, CA,
USA); mouse antiproliferating cell nuclear antigen (PCNA) clone
PC10 DAKO A/S from DAKO Corp. (Carpinteria, CA, USA); and
peroxidase-conjugated goat anti-rat IgG (HþL) and peroxidase-
conjugated rat anti-mouse IgG2a from Serotec Harlan Bioproducts
for Science, Inc. (Indianapolis, IN, USA).
Isolation of mRNA and Northern blot analysis
Polyadenylated mRNA was extracted from 10
7–10
8 cells from
colon cancer cell lines or nonmalignant cell lines growing in
culture by using a FastTrack mRNA isolation kit (Invitrogen Corp.,
San Diego, CA, USA). Northern blot analysis was performed as
previously described (Ellis et al, 1996). After prehybridisation, the
membranes were probed for ephrin-B2 full-length cDNA (the
probe was a generous gift from Dr Renping Zhou, Laboratory for
Cancer Research, College of Pharmacy, Rutgers University,
Piscataway, NJ, USA; Yue et al, 1999), EphB4 (the probe was a
purified polymerase chain reaction product with the primer
sequences as follows: forward, 50-GTCTGACTTTGGCCTTTCCC-
30; reverse, 50-TGACATCACCTCCCACATCA-30), and glyceralde-
hyde-phosphate dehydrogenase (internal control; ATCC). Each
cDNA probe was purified by agarose gel electrophoresis, recovered
by using a QIAEX gel extraction kit (QIAGEN Inc., Chatsworth,
CA, USA), and radiolabelled by a random primer technique with a
commercially available kit (Amersham Life Science Inc., Arlington
Heights, IL, USA). Nylon filters were washed at 651C with
30mmoll
 1 NaCl, 3mmoll
 1 sodium citrate (pH 7.2), and 0.1%
sodium dodecyl sulphate. Autoradiography was then performed.
Subcloning of ephrin-B2 into pcDNA3 and DNA
transfection
Ephrin-B2 was subcloned into the Kpn I/Not I sites of pcDNA3
(Invitrogen), a eukaryotic expression vector driven by the human
cytomegalovirus promoter and containing a neomycin-resistance
gene. Completeness and orientation of the insert were determined
by means of restriction enzyme analyses and DNA sequencing
(Core Sequencing Facilities, M.D. Anderson Cancer Center).
The ephrin-B2 sense plasmid as well as vector plasmid alone
(pcDNA3) were transfected into KM12L4 cells utilising the
FuGENE 6 transfection system, according to the manufacturer’s
protocol (Boehringer Mannheim Co., Indianapolis, IN, USA). At
48h after transfection, medium containing G418 (400mgml
 1) was
used to select for clones. Individual colonies were expanded and
examined for ephrin-B2 expression by Northern blot analysis.
Clones with a high expression of exogenous ephrin-B2 were pooled
to establish an additional experimental cell line, the ephrin-B2 S
pool.
Animals and tumour cell inoculation
Male nude mice (8 weeks old) were obtained from the National
Cancer Institute’s Animal Production Area (Frederick, MD, USA),
acclimated for 1 week, caged in groups of five, and fed a diet of
animal chow and water ad libitum throughout the experiment.
Mice were randomised to one of the four groups, with similar
mean body weights among the four groups. With a 30-gauge
needle and a 1-ml syringe, 200ml (containing 1 10
6 cells) of
KM12L4, pcDNA3-transfected KM12L4, or ephrin-B2-sense trans-
fected KM12L4 (S2 or S pool) cells were injected subcutaneously in
the right upper flank of 10 mice each. Prior to injection, a trypan
blue exclusion test was carried out to assure that cell viability was
greater than 80%. Tumour growth was measured every other day.
Tumour volume was calculated using the formula: volu-
me¼(diameter
2 length)/2. All animal studies were conducted
according to a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) of M.D. Anderson Cancer Center and
were performed in accordance with the UKCCCR guidelines for the
welfare of animals in experimental neoplasia (Workman et al,
1998). All animals were euthanised 15 days after tumour cell
inoculation because of the large volume of the KM12L4 tumours
(maximum size permitted by the IACUC), and the tumours were
harvested for further analysis. Harvested tumours were placed in
10% formalin for paraffin fixation or placed in optimum cutting
temperature (OCT; Miles Inc., Elkhart, IN, USA) solution and snap
frozen for frozen sectioning. This experiment was performed three
times with similar results.
Immunohistochemistry of paraffin-embedded and frozen
tissues and immunofluorescent staining of cells
Paraffin-embedded tumours were sectioned (4–6mm thick),
mounted on positively charged Superfrost slides (Fisher Scientific
Co., Houston, TX, USA), and allowed to dry overnight at room
temperature. Sections were deparaffinised in xylene followed by
100, 95, and 80% ethanol and rehydrated in phosphate-buffered
saline (PBS; pH 7.5). These sections were used for haematoxylin
and eosin (H&E) staining and detection of PCNA. Sections
analysed for PCNA were microwaved for 5min to increase antigen
retrieval before staining, and stained as described below.
Tumours frozen in OCT solution were sectioned (8–10mm
thick), mounted on positively charged Superfrost slides, and air-
dried for 30min. Tissues were fixed in cold acetone (5min), 1:1
acetone/chloroform (5min), and acetone (5min) and then washed
with PBS three times for 3min each. These sections were used for
CD31 staining. Specimens were then incubated with 3% hydrogen
peroxide in PBS (vv
 1) for 12min at room temperature to block
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sendogenous peroxidase. Sections were washed three times for
3min each with PBS (pH 7.5) and incubated for 20min at room
temperature in a protein-blocking solution consisting of PBS
supplemented with 1% normal goat serum and 5% normal horse
serum.
The primary antibodies directed against CD31 and PCNA were
diluted 1:100 and 1:50, respectively, in protein-blocking solution
and applied to the sections, which were then incubated overnight
at 41C. Sections were then rinsed three times for 3min each in PBS
and incubated for 10min in protein-blocking solution before the
addition of peroxidase-conjugated secondary antibody. The
secondary antibodies used to stain for CD31 [peroxidase-
conjugated goat anti-rat IgG (HþL)] and PCNA (peroxidase-
conjugated rat anti-mouse IgG2a) were diluted 1:200 and 1:100,
respectively, in protein-blocking solution. After incubation with
the secondary antibody for 1h at room temperature, the samples
were washed and incubated with stable diaminobenzidine
(Research Genetics, Huntsville, AL, USA) substrate. Staining was
monitored under a bright field microscope, and the reaction was
stopped by washing with distilled water. For the CD31 staining,
sections were counterstained with Gill’s No. 3 haematoxylin
(Sigma Chemical Co.) for 15s and mounted with Universal Mount
(Research Genetics). Control specimens were treated with a similar
procedure except that the primary antibody was omitted.
Ephrin-B2-sense-transfected cells (S2) and vector-transfected
cells (KM12L4/pcDNA3) were seeded in the wells of four-chamber
slides (Fisher Scientific Co.) and cells were grown until 80%
confluent. The cells were fixed with cold acetone (Sigma Chemical
Co.) for 10min and washed with PBS twice for 5min each.
Immunofluorescent staining was performed as previously de-
scribed (Liu et al, 2002) with the following modifications. After the
cells were incubated overnight at 41C with the primary antibody
(ephrin-B2, 1:100 dilution), washed, and incubated with protein-
blocking solution, they were incubated with the Alexa 594-
conjugated secondary antibody (1:400 dilution of Alexa 594 goat
anti-rabbit IgG (HþL); (Molecular Probes, Eugene, OR, USA)) for
60min at room temperature. The slides were then washed with PBS
and the coverslips were mounted on glass slides using mounting
solution consisting of Hoechst 33342 fluorescent dye (Sigma
Chemical Co.) and PBS.
Quantification of tumour microvessel density and tumour
cell proliferation
To quantify tumour microvessel density and tumour cell
proliferation, tumour microvessels (stained for CD31) and
PCNA-positive cells were evaluated by light microscopy and
counted in three random 0.159mm
2 fields at  100 magnification
using a Sony 3-chip camera (Sony, Montvale, NJ, USA) mounted
on a Zeiss universal microscope (Carl Zeiss, Thornwood, NY, USA)
and Optimas Image Analysis software (Bioscan, Edmond, WA,
USA) installed on a Compaq computer with Pentium chip, a frame
grabber, an optical disk storage system, and a Sony Mavigraph UP-
D7000 digital color printer (Tokyo, Japan). Microvessels were
quantified according to the method described by Ahmad et al
(2001).
Determination of functional blood volume/flow in
tumours
Five nude mice were killed and their blood was harvested in
heparinised syringes (approximately 1ml per mouse) for radi-
olabelling. Red blood cells (RBCs) were centrifuged at 1000rpm for
5min and resuspended in 1ml of PBS containing Hank’s balanced
salt solution (HBSS) (Life Technologies). In all, 1mCi of radio-
chromium (
51Cr) (Amersham) was added to label the RBCs. The
labelling reaction was carried out in a 371C water bath with
shaking for 2h. The
51Cr-labelled RBCs were then washed twice
with PBS for 15min each time and resuspended in HBSS. A 0.2-ml
suspension of
51Cr-labelled RBCs was injected intravenously into
the tail vein of tumour-bearing mice ((n¼10/group), B0.05mCi
per mouse). At 10min after injection of
51Cr-labelled RBCs, 10mlo f
blood was collected from the tail vein of each mouse for
radioactive count reading. The mice were then killed, the tumours
were removed, and radioactive counts of the tumours were
recorded with the Packard Auto-Gamma counter (Downers Grove,
IL, USA). The blood volume in the tumours was calculated using
the formula: blood volume (mlg
 1)¼tumour radioactive count
(cpmg
 1)/blood radioactive count (cpmml
 1).
Statistical analysis
Tumour weights, tumour volumes, tumour microvessel densities,
and numbers of PCNA-positive cells were compared between
groups by using one-way analysis of variance (ANOVA). Func-
tional blood volume in tumours (
51Cr labelling) was compared
using the Mann–Whitney U test for nonparametric data. All
analyses were carried out using InStat Statistical Software
(GraphPad Software, San Diego, CA, USA) with Pp0.05 con-
sidered to be significant.
RESULTS
Ephrin-B2 and EphB4 mRNA expression in normal and
colon cancer cell lines
Northern blotting was performed to determine the frequency of
expression of ephrin-B2 and EphB4 in human nonmalignant cell
lines and colon cancer cell lines. All the nonmalignant cell lines
and colon cancer cell lines examined expressed ephrin-B2 and
EphB4 (Figure 1A). However, the expression of EphB4 mRNA was
lower in the nonmalignant cell lines, with the exception of
HUVECs, than in the colon cancer cell lines.
Transfection of Ephrin-B2 in to colon cancer cells and its
effect on tumour growth
Northern blot analysis demonstrated higher levels of ephrin-B2 in
transfected cells (S2 and S pool), as expected (data not shown). In
addition, to confirm that the transfected ephrin-B2 protein
product localised to the cell surface, we performed immunofluore-
scent staining on cells in vitro. In ephrin-B2 transfected cells, we
noted localisation of the protein to the cell surface and its
expression was greater than that in control cells (Figure 1B). As
expected, the ephrin-B2 receptor, EphB4, was unchanged in the
ephrin-B2-sense transfected cells (data not shown). To determine
whether overexpression of ephrin-B2 affects the growth of KM12L4
tumours, we injected KM12L4 tumour cells transfected with a
sense construct for ephrin-B2 subcutaneously in nude mice.
Tumours from ephrin-B2-sense-transfected cells (S2 and S pool)
had significantly smaller volumes (Figure 2A) and weights
(Figure 2B) than did tumours from parental KM12L4 or
pcDNA3-transfected cells (controls). All mice were killed on day
15 since the tumours in the control groups were of maximal size as
outlined by the IACUC. These findings were confirmed in two
subsequent studies.
Effect of ephrin-B2 overexpression on vessel density and
tumour cell proliferation
Immunohistochemical staining for CD31 in tumour sections
demonstrated that tumours from ephrin-B2-sense-transfected
KM12L4 cells (overexpressing ephrin-B2) had significantly higher
tumour vessel counts compared to controls (Po0.0001, Figure 3A).
Immunohistochemical staining for PCNA to determine tumour cell
proliferation rates revealed that ephrin-B2 overexpression led to
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ssignificantly lower numbers of PCNA-positive cells than in
controls (Po0.0001) (Figure 4). However, careful inspection of
the vessel morphology demonstrated small, thin-walled vessels
(Figure 5). Representative results of immunostaining are shown in
Figure 5.
Effect of ephrin-B2 overexpression on functional blood
volume/flow in tumours
Overexpression of ephrin-B2 led to an increase in tumour
angiogenesis (vessel count by CD31 staining) but a decrease in
tumour size and tumour cell proliferation (PCNA staining). This
apparent paradox could be explained by the development of an
inefficient blood supply in the ephrin-B2-overexpressing tumours.
Therefore, we hypothesised that despite more vessels being present
in the ephrin-B2-overexpressing tumours, these tumours have a
decreased functional vascular volume/flow due to inefficient blood
supply. To investigate this hypothesis, we used
51Cr-labelled RBCs
to determine blood volume in the tumours.
51Cr-labelled RBCs
were injected intravenously via the tail vein into tumour-bearing
mice (pcDNA3 and ephrin-B2 S2 transfectant, 10 mice/each
group). Tumours from ephrin-B2-sense-transfected cells had a
significantly lower blood volume per gram of tissue than did
tumours from pcDNA3-transfected cells (P¼0.0288) (Figure 3B).
DISCUSSION
Ephrins consist of two classes: ephrin-As, which bind to the
membrane via a glycosylphosphatidylinositol anchor, and ephrin-
Bs, which interact with their receptors through the transmembrane
cytoplasmic domain. Ephrins/Ephs are essential mediators in the
development of the nervous (Flanagan and Vanderhaeghen, 1998)
and cardiovascular systems (Wang et al, 1998).
Among the ephrin family members, ephrin-B2 is critically
important for embryologic vascular development. Ephrin-B2
knockout mice resulted in severe vascular developmental defects
during embryogenesis (Wang et al, 1998; Adams et al, 1999). In
murine models, ephrin-B2 is expressed in the arterial ECs but not
in the venous ECs (Wang et al, 1998; Adams et al, 1999). Ephrin-B2
is also expressed in the vascular smooth muscle cells of arteries
(Shin et al, 2001). Wang et al (1998) reported that ephrin-B2s on
arterial ECs interact with EphB4s on venous ECs, and Zhang et al
(2001) showed that stromal cells expressing ephrin-B2 are involved
in vascular network formation and proliferation of ECs. These data
suggest that the interaction of ephrin-B2 and EphB4 leads to
reciprocal signalling between arterial ECs, venous ECs, and
surrounding vascular supportive cells (Wang et al, 1998; Zhang
et al, 2001).
Further studies suggest that ephrin-B2 is involved in tumour
angiogenesis. Shin et al (2001) observed ephrin-B2-expressing ECs
within the vasculature of tumours, and ephrin-Bs and Ephs have
been found to be expressed by a variety of human solid tumours
Figure 1 Expression of ephrin-B2 and EphB4 in cell lines and
immunofluorescent staining of Ephrin-B2 in transfected colon cancer cell
lines. (A) Coexpression of ephrin-B2 and EphB4 mRNA in the various
normal and colon cancer cell lines. GAPDH, glyceraldehyde-phosphate
dehydrogenase. (B) Immunofluorescent staining with ephrin-B2 was
performed on ephrin-B2 transfected (S2) and vector transfected cells.
Representative pictures showed that the staining of ephrin-B2 was much
stronger (a, red) on the cell surface (c, merged image) in ephrin-B2-sense-
transfected KM12L4 cells compared to the pcDNA3-transfected cells
(d, red and f, merged image).
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Figure 2 Effect of ephrin-B2 overexpression on the growth of tumours
from ephrin-B2-sense-transfected KM12L4 cells in nude mice. (A) Mean
tumour volumes were determined every other day following subcutaneous
injection (n¼10). On days 7–15, the mean volumes of tumours from
ephrin-B2-sense-transfected cells (S2 and S pool) were significantly smaller
than those of control tumours from parental KM12L4 cells or vector-
transfected cells (*Po0.0001, ANOVA). Error bars indicate the standard
error (s.e.m.) of the mean. (B) After 15 days, the mice injected with ephrin-
B2-sense-transfected KM12L4 cells (white bars) had significantly less heavy
tumours than did control mice (black bars) (*Po0.0001, ANOVA). Error
bars indicate s.e.m. of the mean.
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sand human tumour cell lines (Vogt et al, 1998; Tang et al, 1999a,
2000; Takai et al, 2001; Liu et al, 2002; Varelias et al, 2002).
Overexpression of ephrin-Bs/Ephs is associated with increased
tumour growth, increased tumorigenicity, and poorer prognosis in
human osteosarcoma, endometrial cancer, and melanomas (Vogt
et al, 1998; Takai et al, 2001; Varelias et al, 2002). Vogt et al (1998)
reported that ephrin-B2 mRNA expression is higher in metastatic
melanoma cell lines than in isogenic primary melanoma cell lines
and higher in metastatic human tumours compared to primary
melanomas. Vogt et al also showed a significant increase in
ephrin-B2 mRNA expression in primary melanoma cell lines
selected for increased tumorigenicity.
We transfected the full-length ephrin-B2 cDNA into the human
colon cancer cell line KM12L4 and found that the in vivo growth of
ephrin-B2-overexpressing tumours was significantly decreased
compared to control tumours. Immunohistochemical staining
showed that the tumours overexpressing ephrin-B2 had increased
vessel counts but decreased tumour cell proliferation. Theoreti-
cally, decreases in tumour growth can be attributed to several
broad categories of processes: (1) increased tumour cell death, (2)
decreased tumour cell proliferation, and (3) alterations in
angiogenesis that can affect both processes. Using Western blot
analysis, we determined the protein expression profiles for
regulators of the cell cycle (cyclins A, D1, D3, and E; cyclin-
dependent kinases 2 and 4; and cyclin-dependent kinase inhibitors
p21 and p27) and of apoptosis (the oncogene murine double
minute 2; tumour suppressor genes pRB and p53; and apoptosis-
related genes caspases 2, 3, and 7) in ephrin-B2-transfected and
control cells. These studies were carried out to determine whether
ephrin-B2 transfection altered any of these parameters that could
directly affect tumour growth in vivo. None of these proteins was
altered by ephrin-B2 transfection (data not shown). Furthermore,
cell cycle analysis by fluorescence-activated cell sorting showed
that the cell cycle distribution of ephrin-B2 transfectants was the
same as that of control cells (data not shown). In addition, an in
vitro analysis of cell proliferation/number (MTT assay) likewise
did not show any differences among groups (data not shown).
Therefore, based on these analyses, we concluded that the decrease
in tumour growth observed in the current study was not due to
changes in the cell cycle or tumour cell apoptosis. We therefore
hypothesised that despite the increase in microvessel density,
these vessels were dysfunctional. To evaluate the ‘functional’
tumour vascular volume, we injected
51Cr-labelled RBCs and
harvested blood and tumours to obtain the relative radioactivity.
Tumours from ephrin-B2-transfected cells had a significantly
smaller tumour blood volume despite having an increase in
microvessel density. These data demonstrated that overex-
pression of ephrin-B2 can increase tumour microvessel density
but that these vessels may be ‘dysfunctional’. The fact that these
tumour vessels were dysfunctional is similar to the findings of
Jain and co-workers (Jain, 2001). Our observation suggests that
vessel density, although typically associated with angiogenesis,
does not always reflect the functional status of the vascular
network in tumours. Functional studies such as noninvasive
imaging techniques may more accurately reflect the true functional
status of the tumour microvascular bed than do anatomic or
morphologic studies.
In summary, our study demonstrated two novel findings with
potentially important implications. The first was that overexpres-
sion of ephrin-B2 on tumour cells can markedly decrease the
growth of SQ colon cancer xenografts. The second interesting
finding was that this decrease in tumour growth occurred despite
an increase in tumour vessel counts. Our experiment with
51Cr-
labelled RBCs suggested that tumour vessel count does not always
correlate with the ‘functional status’ of the vasculature. This
further questions the value of vessel counts as a measure of
angiogenic or antiantiangiogenic activity (Hlatky et al, 2002) and
suggests that functional studies more accurately measuring blood
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Figure 3 Effect of ephrin-B2 overexpression on tumour vessel counts
and blood volume in tumours. (A) Immunohistochemical staining for CD31
in tumour sections was performed. The mean vessel count in tumours from
mice injected with ephrin-B2-sense-transfected KM12L4 cells (white bars)
was significantly greater than in control tumours (black bars) (*Po0.0001,
ANOVA). Error bars indicate s.e.m. of the mean. HPF, high-power field.
(B)
51Cr-labelled RBCs suspended in HBSS were injected into the tail vein
of tumour-bearing nude mice. The mean blood volume in tumours from
ephrin-B2-sense-transfected KM12L4 cells (S2) was significantly less than in
control tumours from vector-transfected cells (*P¼0.0288, nonparametric
test). Error bars indicate s.e.m. of the mean.
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Figure 4 Effect of ephrin-B2 sense transfection on tumour cell
proliferation. Immunohistochemical staining for PCNA in tumour sections
was performed. The mean number of PCNA-positive cells in tumours from
mice injected with ephrin-B2-sense-transfected KM12L4 cells (white bars)
were significantly lower than in control tumours (black bars) (*Po0.0001,
ANOVA). Error bars indicate s.e.m. of the mean. HPF, high-power field.
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network than morphologic or anatomic studies.
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